Compare iShares MSCI Canada (TSX) (EWC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Cassava Sciences Inc — how do they compare? iShares MSCI Canada (TSX) trades at $61.53, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWC | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $4.64 |
52-Week Low | $47.00 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.
Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
